Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Chinese Journal of Experimental Traditional Medical Formulae ; 29(8):220-228, 2023.
Article in Chinese | EMBASE | ID: covidwho-20238680

ABSTRACT

Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method(s): Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge InfrastructureCNKI,VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result(s): Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019COVID-19. Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion(s):Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

2.
Chinese Journal of Experimental Traditional Medical Formulae ; 29(8):220-228, 2023.
Article in Chinese | EMBASE | ID: covidwho-2298813

ABSTRACT

[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

3.
Chinese Journal of Experimental Traditional Medical Formulae ; 29(8):220-228, 2023.
Article in Chinese | EMBASE | ID: covidwho-2268967

ABSTRACT

[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

4.
Chinese Journal of Experimental Traditional Medical Formulae ; 29(8):220-228, 2023.
Article in Chinese | EMBASE | ID: covidwho-2268966

ABSTRACT

[] Objective: To analyze relevant literature on Lianhua Qingwen preparations and clarify the research advances and hot spots in this field,so as to provide references for clinical rational application and further research. Method: Literature related to Lianhua Qingwen preparations in the recent 10 years was retrieved from six databases,including China National Knowledge Infrastructure(CNKI),VIP,Wanfang Data, PubMed,and Web of Science,followed by management and analysis by NoteExpress and CiteSpace. Result: Finally,344 and 76 Chinese and English research articles were included,and the number of publications increased in recent years. The research articles were published in 162 Chinese and 48 English journals. Shijiazhuang Yiling Pharmaceutical Co.,Ltd. and Guangzhou Medical University were institutions with the largest number of Chinese and English publications,respectively. LIU Minyan was the author who had published the most articles. Keywords with high frequency included clinical efficacy,Lianhua Qingwen,inflammatory factors,traditional Chinese medicine,and coronavirus disease-2019(COVID-19). Nineteen clusters,including clinical efficacy,Chinese medicine,Lianhua Qingwen,COVID-19,and influenza A virus,and 47 emergent keywords,including herpes zoster,pneumonia,inflammatory factors,influenza,and gut microbiota,were generated. Conclusion:Cooperation and exchanges in this field are insufficient. Research focuses on the clinical efficacy of Lianhua Qingwen in the treatment of COVID-19 and other diseases,pharmacological action and mechanism of antiviral drugs,and micro-mechanism research focuses on related pathways and target proteins,as well as the combination of Chinese and western medicines.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

6.
Topics in Antiviral Medicine ; 30(1 SUPPL):152-153, 2022.
Article in English | EMBASE | ID: covidwho-1880804

ABSTRACT

Background: Neurological manifestations are a major complication of sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and likely contribute to symptoms of "long COVID". Elucidating the mechanisms that underlie neuropathogenesis in infection is critical for identifying or developing viable therapeutic strategies. While neurological injury in infection is varied, cerebrovascular disease is seen at a high frequency among patients over 50 years of age. Additionally, microhemorrhages and hypoxic-ischemic injury are often described in brain autopsy series of human subjects who died from COVID-19. Here, we report neuropathology in aged SARS-CoV-2 infected non-human primates (NHPs) is consistent with that observed in aged human subjects and provide insight into the underlying cause. Methods: Four adult Rhesus macaques and four African green monkeys were inoculated with the 2019-nCoV/USA-WA1/2020strain of SARS-CoV-2 via a multi-route mucosal or aerosol challenge. Two of each species were included as age-matched controls. Frontal, parietal, occipital, and temporal lobes, basal ganglia, cerebellum, and brainstem were interrogated through histopathological and immunohistochemical techniques to identify and characterize the observed pathology. Results: Like humans, pathology was variable but included wide-spread inflammation with nodular lesions, neuronal injury, and microhemorrhages. Neuronal degeneration and apoptosis were confirmed with FluoroJade C and cleaved caspase 3 IHC, which showed foci of positivity, particularly among cerebellar Purkinje cells. This was seen even among infected animals that did not develop severe respiratory disease but was not seen in age-matched controls. Significant upregulation of the alpha subunit of hypoxia inducible factor 1 (HIF1-α), indicative of tissue hypoxia, was observed in brain of all infected animals, regardless of disease severity. Sparse virus was detected in brain endothelial cells but did not associate with the severity of CNS injury. Conclusion: SARS-CoV-2 infected NHPs are a viable animal model for advancing our current understanding of infection-associated neuropathogenesis. Upregulation of HIF1-α in brain of infected animals suggests cerebral hypoxia may underlie or contribute to neuroinflammation and neuronal injury/death and may provide some insight into neurological manifestations observed among asymptomatic patients or those only suffering mild disease.

9.
Journal of Investigative Medicine ; 69(2):440-440, 2021.
Article in English | Web of Science | ID: covidwho-1117086
SELECTION OF CITATIONS
SEARCH DETAIL